BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 953 filers reported holding BAXTER INTL INC in Q2 2014. The put-call ratio across all filers is 0.79 and the average weighting 0.4%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $6,311,000 | +201.0% | 77,621 | +143.7% | 0.10% | +162.2% |
| Q4 2018 | $2,097,000 | -28.4% | 31,854 | -16.2% | 0.04% | -17.8% |
| Q3 2018 | $2,930,000 | +6.7% | 38,011 | +2.2% | 0.04% | -6.2% |
| Q2 2018 | $2,746,000 | +18.3% | 37,188 | +4.2% | 0.05% | +17.1% |
| Q1 2018 | $2,322,000 | -2.0% | 35,700 | -2.6% | 0.04% | -10.9% |
| Q4 2017 | $2,370,000 | -13.5% | 36,665 | -16.0% | 0.05% | -13.2% |
| Q3 2017 | $2,739,000 | +2.2% | 43,650 | -1.4% | 0.05% | -1.9% |
| Q2 2017 | $2,680,000 | +16.9% | 44,271 | +0.2% | 0.05% | +14.9% |
| Q1 2017 | $2,292,000 | +28.3% | 44,194 | +9.6% | 0.05% | +23.7% |
| Q4 2016 | $1,787,000 | +102.8% | 40,313 | +235.3% | 0.04% | +58.3% |
| Q4 2014 | $881,000 | +1.3% | 12,024 | -0.8% | 0.02% | -4.0% |
| Q3 2014 | $870,000 | +4.4% | 12,127 | +5.3% | 0.02% | +4.2% |
| Q2 2014 | $833,000 | -25.8% | 11,521 | -24.5% | 0.02% | -29.4% |
| Q1 2014 | $1,122,000 | +7.1% | 15,253 | +1.3% | 0.03% | +6.2% |
| Q4 2013 | $1,048,000 | +168.0% | 15,063 | +166.6% | 0.03% | +128.6% |
| Q2 2013 | $391,000 | – | 5,651 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Soditic Asset Management LLP | 147,620 | $7,951,000 | 9.91% |
| NUANCE INVESTMENTS, LLC | 5,429,702 | $292,444,000 | 6.51% |
| Endurant Capital Management LP | 245,093 | $13,201,000 | 4.30% |
| Veritas Asset Management LLP | 8,589,401 | $462,625,000 | 3.83% |
| GENERATION INVESTMENT MANAGEMENT LLP | 11,876,040 | $639,644,000 | 3.80% |
| Sivik Global Healthcare LLC | 120,000 | $6,463,000 | 3.59% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 480,500 | $25,880,000 | 3.31% |
| Integral Health Asset Management, LLC | 300,000 | $16,158,000 | 3.14% |
| Boothe Investment Group, Inc. | 89,078 | $4,798,000 | 3.11% |
| Glenview Capital Management | 2,257,019 | $121,563,000 | 3.04% |